Supernus Pharmaceuticals, Inc. (SUPN)
| Market Cap | 2.93B +63.1% |
| Revenue (ttm) | 776.83M +16.3% |
| Net Income | -29.02M |
| EPS | -0.51 |
| Shares Out | 58.04M |
| PE Ratio | n/a |
| Forward PE | 18.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 281,097 |
| Open | 49.61 |
| Previous Close | 49.37 |
| Day's Range | 48.84 - 50.55 |
| 52-Week Range | 30.83 - 59.68 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 61.60 (+21.88%) |
| Earnings Date | May 5, 2026 |
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SUPN stock is "Strong Buy." The 12-month stock price target is $61.6, which is an increase of 21.88% from the latest price.
News
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong revenue growth, driven by ONAPGO's rebound, robust Qelbree and ZURZUVAE performance, and improved operating results. Guidance for 2026 was reiterated, with a solid cash position and no debt supporting future growth.
Supernus Announces First Quarter 2026 Financial Results
ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...
Supernus enters into asset purchase agreement with Navitor
In a regulatory filing, the company states: “On April 1, Supernus (SUPN) Pharmaceuticals entered into an Asset Purchase Agreement, together with related ancillary transaction documents, with Navitor P...
Supernus Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Record 2025 revenue and a revamped portfolio with four growth drivers set the stage for 2026, with balanced contributions expected from Qelbree, Gocovri, Zurzuvae, and ONAPGO. Continued investment in marketing and R&D supports strong revenue growth and a robust pipeline, with key data readouts anticipated in 2027.
Supernus Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The company has resolved ONAPGO supply issues and resumed new patient starts, with strong demand and a $45–$70 million revenue outlook. Qelbree and ZURZUVAE continue to grow, supported by increased investment and education, while pipeline assets advance toward 2027 data.
Supernus price target raised to $65 from $60 at TD Cowen
TD Cowen raised the firm’s price target on Supernus (SUPN) to $65 from $60 and keeps a Buy rating on the shares. The firm updated its model following Q4 results…
Supernus Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 revenues of $719 million were driven by strong growth in Qelbree, GOCOVRI, Zurzuvae, and ONAPGO, with successful integration of Sage Therapeutics and resolution of ONAPGO supply constraints. 2026 guidance projects continued double-digit revenue growth and robust product demand.
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four g...
Supernus Pharmaceuticals to Participate in March Investor Conferences
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Lunai Bioworks, Inc. Issues Letter to Shareholders
SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial.
Supernus price target raised to $55 from $50 at Stifel
Stifel analyst Annabel Samimy raised the firm’s price target on Supernus (SUPN) to $55 from $50 and keeps a Hold rating on the shares as part of a 2026 outlook…
Supernus Pharmaceuticals Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025
Integration of the Sage acquisition is ahead of plan, with $200M in annualized synergies targeted. ZURZUVAE and Qelbree are both experiencing strong demand-driven growth, while APOKYN supply constraints are being addressed through alternative manufacturing. Pipeline assets SPN-820 and SPN-817 are advancing in clinical development.
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
Supply constraints for ONAPGO are being addressed through current and alternative suppliers, with FDA involvement and long-term plans for a second supplier. Demand remains strong, especially among advanced Parkinson’s patients, and ZURZUVAE is expanding in the postpartum depression market, primarily through OB-GYNs.
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Revenue guidance is $685–$705 million, driven by four CNS products, with Qelbree and Onapgo showing strong growth. Onapgo faces supply constraints, while Zurzuvae is expanding in postpartum depression. Business development and pipeline expansion remain key priorities.
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw strong revenue growth from key products, with ONAPGO, Qelbree, GOCOVRI, and ZURZUVAE driving 78% of total revenues. Guidance for 2025 was raised, though ONAPGO supply constraints are limiting new patient starts. Cash remains strong with no debt.
Supernus Announces Third Quarter 2025 Financial Results
ROCKVILLE, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus initiated with a Buy at BofA
BofA initiated coverage of Supernus (SUPN) with a Buy rating and $65 price target citing what it sees as the “underappreciated” branded central nervous system growth drivers with its treatments…
Supernus price target raised to $60 from $45 at TD Cowen
TD Cowen raised the firm’s price target on Supernus (SUPN) to $60 from $45 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3…